Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage cell therapy company developing multi-antigen targeted T-cell therapies, with a focus on its MAR-T platform and lead candidates such as MT-601 and MT-401. The company does not yet sell approved products and currently funds development through grants, equity financing, and collaborations with research and manufacturing partners.

−343,0 %

−46,2 %

8.39

8.39

— Marker Therapeutics, Inc.
%
Cell therapy product candidates0% Clinical-stage MAR-T and OTS cell therapies being developed for AML, MDS, and other cancers.
Research grants100% Government and institutional grants that fund qualifying R&D and clinical trial activity.
Manufacturing and process development0% Technology transfer, process development, and outsourced cGMP manufacturing support for pipeline programs.

Marker Therapeutics' direct economic counterparties are not commercial customers but grant agencies, clinical...

  • Government grant agenciesprimary

    CPRIT, FDA, and NIH fund specific development programs and reimburse qualifying research costs.

  • Clinical trial sites and investigatorsprimary

    Academic and clinical centers run studies for MT-401 and MT-601 and generate the data needed for approval.

  • CDMO and manufacturing partnersprimary

    Cellipont and other third parties provide technology transfer, process development, and cGMP manufacturing.

  • Future oncology treatment centersemerging

    If approved, hospitals and cancer centers would purchase and administer the therapies.

Marker Therapeutics is headquartered in the United States and its development, manufacturing, and regulatory activities...

  • •United States is the core operating and regulatory market
  • •Houston, Texas has been the main manufacturing base
  • •Clinical and cGMP work is now outsourced to U.S. partners
  • •FDA, NIH, and SEC actions directly affect development timing
  • •Capital access depends on U.S. public markets and investor appetite

The company is focused on advancing MT-601 and MT-401 through clinical development while preserving cash through...

01
Clinical advancement of MT-601short-term

The lead program needs manufacturing scale-up and clinical data to validate the MAR-T platform.

02
Progress MT-401 OTS developmentshort-term

The off-the-shelf AML program could broaden the platform and address rapidly progressing diseases.

03
Preserve liquidity and extend runwayshort-term

The company has no commercial revenue and must fund operations through external capital and grants.

04
Outsource manufacturing and scale process qualitymedium-term

Third-party cGMP manufacturing reduces capital intensity and supports commercial scalability if approved.

Marker Therapeutics faces classic clinical-stage biotech risks: program failure, regulatory delay, and dependence on...

critical

Clinical development failure

The company has no approved products, so negative trial results would impair the core asset base.

Scope
MT-601, MT-401, and future pipeline candidates
Materiality
High
critical

Financing and liquidity shortfall

Operations are funded through equity, debt, and grants, with no recurring product revenue.

Scope
Near-term operating runway and dilution risk
Materiality
High
high

Regulatory delay or disruption

FDA review timing and NIH/FDA grant administration can be slowed by staffing, budget, or shutdown issues.

Scope
INDs, trial amendments, and future approvals
Materiality
High
high

Manufacturing execution risk

The company relies on third parties for cGMP manufacturing and technology transfer.

Scope
Product quality, supply continuity, and scale-up
Materiality
High
high

Dilution from equity financing

ATM and other equity raises can materially dilute existing shareholders.

Scope
Common stock holders
Materiality
High
Grant income recognition
Quarterly revenue volatility and deferred revenue balances
Restricted cash and deferred revenue
Liquidity presentation and liability recognition
Going concern assessment
Financial statement basis and investor risk perception
Stock-based compensation and ATM financing
Net loss, share count, and per-share metrics

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

CELZ · Biological Products, (No Diagnostic Substances)

INSMED Inc

INSM · Pharmaceutical Preparations

4D Molecular Therapeutics, Inc.

FDMT · Biological Products, (No Diagnostic Substances)

Merck & Co., Inc.

MRK · Pharmaceutical Preparations

CAPRICOR THERAPEUTICS, INC.

CAPR · Pharmaceutical Preparations

Modular Medical, Inc.

MODD · Surgical & Medical Instruments & Apparatus

: 28.4.2026